what is cjc 1295 with ipamorelin CJC-1295 (NO DAC) + 5mg+5mg CJC-1295 & Ipamorelin Therapy in

Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges

Agarwal, A

CJC/IPA: Growth Hormone Optimization What it is: CJC-1295 and Ipamorelin (IPA) are peptides that stimulate the bodys natural production of growth hormone

Cognitive function: A randomised controlled trial by Baker et al